As a famous antibody service provider in the world, Creative Biolabs has consistently focused on the development and manufacture of in vitro diagnostic (IVD) antibodies for the diagnosis of many different diseases. We’re capable of offering high-affinity, high-efficiency antibodies against specific markers of lung cancer, which brings about valuable information for the diagnosis, treatment, and prognosis of lung cancer. Especially, carbonic anhydrase XII (CAXII) has been regarded as a reliable biomarker in lung cancer and we can produce corresponding antibody products for diagnostic use.
Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes, responsible for catalyzing the reversible hydration of carbon dioxide to form bicarbonate (HCO3-) and protons (H+). They’re implicated in a number of biological processes, such as respiration, calcification, acid-base balance, bone resorption, and the formation of saliva, aqueous humor, cerebrospinal fluid, and gastric acid. CAXII, also known as carbonic anhydrase 12 (CA12), carbonate dehydratase XII, and tumor antigen HOM-RCC-3.1.3, is also a zinc-containing enzyme belonging to the carbonic anhydrase family. It is a type I transmembrane protein which is found highly expressed in normal tissues, including the kidney, pancreas, and colon, and is overexpressed in 10% of clear cell renal carcinomas. Hypoxic conditions can activate transcription and translation of CAXII and enhanced expression is often present in several tumors.
Fig.1 The protein structure of CAXII.1
Lung cancer has the highest cancer-associated morbidity and mortality rate around the world. The pattern of protein expression in cancers is under the affection of nutrient stress, hypoxia, and low pH, which determines the survival of tumor cells and the development of neoplasms. Among the corresponding gene products, the isoenzyme of CA family, CAXII, is induced under hypoxic conditions in many types of tumors and their expression is downregulated when returned to the normoxia pattern.
Some studies generated monoclonal antibodies using pulmonary adenocarcinoma (AD)-derived A549 cells as antigens to develop serodiagnostic markers for lung cancer. In figure 2, the CAXII was expressed only in A549 cells as a 40-kDa protein, and no clear band was observed in other cell types. Meanwhile, membranous expression of CAXII was detected only in A549 cells by immunohistochemical analyses. Combined with other evidence, the serum CAXII levels should be applicable markers distinguishing lung cancer patients from healthy controls.
Fig.2 Expression of CAXII antibody in lung cancer cell lines and tissues. (Kobayashi, M., 2012)
In addition, a report assessed the prognostic value of CAXII tumor tissues expression in patients with non-small cell lung cancer (NSCLC). The 555 tumor samples were immunostained for CAXII on tissue microarrays and the results illustrated that a high CAXII expression level was related to a better outcome in a large series of patients with resectable NSCLC.
Evidence has supported that CAXII is regarded as a novel diagnostic and prognostic biomarker for lung cancer. At Creative Biolabs, we’re specialized in providing IVD antibody development services for CAXII marker and producing different formats of antibodies (e.g. polyclonal, monoclonal, and recombinant). We can tailor one-stop, custom-oriented service packages to develop antibodies with both high specificity and affinity.
If you’re interested in our services, please contact us for more information or directly send us an inquiry.
Reference
For Research Use Only.
